acute promyelocytic leukemia
GPTKB entity
Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
leukemia
|
| gptkbp:advertising |
APML_awareness_month
Leukemia_&_Lymphoma_Society_initiatives |
| gptkbp:aftermath |
approximately 1-2 cases per 100,000 people
|
| gptkbp:associatedWith |
retinoic acid syndrome
DIC_(disseminated_intravascular_coagulation) |
| gptkbp:barrelLength |
approximately 80-90% with treatment
varies by age and health status |
| gptkbp:causedBy |
PML-RARA fusion gene
|
| gptkbp:characteristics |
coagulation abnormalities
hypergranular_promyelocytes promyelocytes_in_blood |
| gptkbp:classification |
subtype of acute myeloid leukemia
|
| gptkbp:clinicalTrials |
ASCO guidelines
ongoing research for new therapies cytogenetic abnormalities immunophenotyping results morphological features in blood smear NCCN_guidelines |
| gptkbp:commonName |
young adults
middle-aged individuals |
| gptkbp:diseaseResistance |
blood tests
more common in males bone marrow biopsy good with treatment higher incidence in certain ethnic groups |
| gptkbp:firstDescribedBy |
in the 1970s
|
| gptkbp:geneticDiversity |
PML gene
RARA gene |
| gptkbp:historicalSignificance |
first leukemia linked to a specific genetic mutation
pioneered_use_of_ATRA_in_treatment |
| https://www.w3.org/2000/01/rdf-schema#label |
acute promyelocytic leukemia
|
| gptkbp:impact |
chemotherapy
all-trans retinoic acid (ATRA) arsenic trioxide relapse possible remission possible |
| gptkbp:relatedPatent |
thrombosis
organ failure infection risk |
| gptkbp:researchFocus |
genetic studies
targeted therapies immunotherapy |
| gptkbp:riskManagement |
genetic predisposition
exposure to benzene previous chemotherapy |
| gptkbp:runnerUp |
regular monitoring required
blood tests needed bone marrow evaluation |
| gptkbp:supports |
patient advocacy groups
APML_support_organizations |
| gptkbp:symptoms |
anemia
bruising bleeding |